BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 15001240)

  • 1. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer.
    Koong AC; Le QT; Ho A; Fong B; Fisher G; Cho C; Ford J; Poen J; Gibbs IC; Mehta VK; Kee S; Trueblood W; Yang G; Bastidas JA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1017-21. PubMed ID: 15001240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
    Koong AC; Christofferson E; Le QT; Goodman KA; Ho A; Kuo T; Ford JM; Fisher GA; Greco R; Norton J; Yang GP
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):320-3. PubMed ID: 16168826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiation therapy boost in locally advanced pancreatic cancer.
    Seo Y; Kim MS; Yoo S; Cho C; Yang K; Yoo H; Choi C; Lee D; Kim J; Kim MS; Kang H; Kim Y
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1456-61. PubMed ID: 19783379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.
    Goodman KA; Wiegner EA; Maturen KE; Zhang Z; Mo Q; Yang G; Gibbs IC; Fisher GA; Koong AC
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):486-93. PubMed ID: 20350791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study.
    Méndez Romero A; Wunderink W; Hussain SM; De Pooter JA; Heijmen BJ; Nowak PC; Nuyttens JJ; Brandwijk RP; Verhoef C; Ijzermans JN; Levendag PC
    Acta Oncol; 2006; 45(7):831-7. PubMed ID: 16982547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients.
    Wulf J; Haedinger U; Oppitz U; Thiele W; Mueller G; Flentje M
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):186-96. PubMed ID: 15337555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoradiotherapy for locally advanced pancreatic cancer: a radiotherapy dose escalation and organ motion study.
    Henry AM; Ryder WD; Moore C; Sherlock DJ; Geh JI; Dunn P; Price P
    Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):541-7. PubMed ID: 18562186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
    Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Shirai Y; Nakagawa A; Kawakami H; Uno T; Ito H; Saisho H
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):219-24. PubMed ID: 17189072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CyberKnife frameless stereotactic radiosurgery for spinal lesions: clinical experience in 125 cases.
    Gerszten PC; Ozhasoglu C; Burton SA; Vogel WJ; Atkins BA; Kalnicki S; Welch WC
    Neurosurgery; 2004 Jul; 55(1):89-98; discussion 98-9. PubMed ID: 15214977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalation of concurrent hypofractionated radiotherapy and continuous infusion 5-FU-chemotherapy in advanced adenocarcinoma of the pancreas.
    Zimmermann FB; Jeremic B; Lersch C; Geinitz H; Hennig M; Molls M
    Hepatogastroenterology; 2005; 52(61):246-50. PubMed ID: 15783041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region.
    Siddiqui F; Patel M; Khan M; McLean S; Dragovic J; Jin JY; Movsas B; Ryu S
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1047-53. PubMed ID: 19327895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.